Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 468 participants.

Also called NCT07537088

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 468 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07537088
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07537088. Randomized; no masking; primary purpose treatment. Start 2026-05 (anticipated); primary completion 2027-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease
Condition
T2DM (Type 2 Diabetes Mellitus)
Intervention (Drug)
Dulaglutide
Intervention (Drug)
SGLT2i
Intervention (Drug)
Finerenone
Lead sponsor
First Affiliated Hospital of Wannan Medical College (class: other)

Record details

Record id
cardio:ct-nct07537088
Content hash
7c962b561aaba63eed43f35df2f295e7919d1064860dcbbba1d4eb48f2d2d045